Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
In the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimm...
Main Authors: | BL Johnston, JM Conly |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2006-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2006/876252 |
Similar Items
-
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
by: David Baker, et al.
Published: (2020-02-01) -
Clostridium difficile: The Evolving Story
by: BL Johnston, et al.
Published: (2007-01-01) -
Hur skiljer sig effekt och säkerhet mellan natalizumab och alemtuzumab vid multipel skleros (MS)?
by: Svensson, Lisa
Published: (2017) -
Community-Associated Methicillin-Resistant Staphylococcus aureus: Continuing to Evolve
by: BL Johnston, et al.
Published: (2008-01-01) -
Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
by: Katja Akgün, et al.
Published: (2018-03-01)